Dentium Co Ltd

Dentium maintains a debt-to-equity ratio of 0.51, indicating a moderate reliance on debt financing, while its current ratio of 1.44 suggests adequate short-term liquidity to cover obligations. However, the company's free cash flow is negative at -17.7 billion KRW, and capital expenditures are substantial at -53.6 billion KRW, signaling ongoing investment in operations. The negative net cash position after subtracting total debt raises concerns about liquidity risk. Profitability metrics show a return on equity (ROE) of 2.92% and a return on assets (ROA) of 1.76%, both below the industry median for medical equipment firms, which typically exceed 4% ROE and 2.5% ROA. Gross profit of 218.1 billion KRW represents 63% of revenue, but operating income of 43.1 billion KRW (12.5% margin) and net income of 16.4 billion KRW (4.7% margin) suggest pressure from operating and non-operating expenses. The company's revenue is concentrated in a single business segment focused on dental implants and related products, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the Korean healthcare sector. Dentium's revenue growth has not been disclosed in the latest financials, but analyst price targets range from 50,000 to 90,000 KRW, with a mean of 73,400 KRW and a median of 70,000 KRW. The mean recommendation of 2.00 (Buy) indicates positive sentiment, though the negative free cash flow and high capital expenditures may constrain near-term growth. Risk factors include liquidity concerns due to negative net cash and a medium liquidity risk rating. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the capital-intensive nature of the medical equipment industry and the need for ongoing R&D could lead to future dilution if financing is required. Recent events include no disclosed filings or transcripts in the provided data. Analysts have issued four Buy and one Hold recommendation, with no Strong Buy beyond one, suggesting cautious optimism about the company's long-term prospects.